Im Bereich klinisch relevanter Dasatinib-Konzentrationen betrug die Plasmaproteinbindung in in-vitro-Experimenten etwa 96%.
At clinically relevant concentrations of dasatinib, binding to plasma proteins was approximately 96% on the basis of in vitro experiments.